Foghorn Therapeutics is a clinical-stage precision oncology biotechnology company targeting the chromatin regulatory system to correct abnormal gene expression. Using its proprietary Gene Traffic Control platform, Foghorn discovers small molecule therapeutics including enzymatic inhibitors, protein degraders, and transcription factor disruptors. Its lead candidate FHD-909 (LY4050784), a selective SMARCA2 ATPase inhibitor developed with Eli Lilly, entered Phase 1 clinical trials in October 2024 for SMARCA4-mutated cancers, primarily non-small cell lung cancer.
expected 2026-12-31
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001628280-26-016814 | EDGAR | 69K words |
| 2025-03-06 | 2024-12-31 | 0001628280-25-010933 | EDGAR | 81K words |
| 2024-03-07 | 2023-12-31 | 0001628280-24-009539 | EDGAR | 82K words |
| 2023-03-09 | 2022-12-31 | 0001628280-23-007297 | EDGAR | 73K words |
| 2022-03-10 | 2021-12-31 | 0001628280-22-005753 | EDGAR | 91K words |
| 2021-03-18 | 2020-12-31 | 0001193125-21-085777 | EDGAR | 80K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001628280-26-053819 | EDGAR | 17K words |
| 2025-11-05 | 2025-09-30 | 0001628280-25-049238 | EDGAR | 17K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037606 | EDGAR | 16K words |
| 2025-05-14 | 2025-03-31 | 0001628280-25-025312 | EDGAR | 14K words |
| 2024-11-04 | 2024-09-30 | 0001628280-24-045006 | EDGAR | 16K words |
| 2024-08-08 | 2024-06-30 | 0001628280-24-035867 | EDGAR | 15K words |
| 2024-05-06 | 2024-03-31 | 0001628280-24-020455 | EDGAR | 13K words |
| 2023-11-02 | 2023-09-30 | 0001628280-23-036187 | EDGAR | 17K words |
| 2023-08-04 | 2023-06-30 | 0001628280-23-027402 | EDGAR | 17K words |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016255 | EDGAR | 16K words |
| 2022-11-08 | 2022-09-30 | 0001628280-22-028930 | EDGAR | 18K words |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021958 | EDGAR | 18K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-10-01 | 0001628280-26-064102 | EDGAR | 1K words |
| 2026-08-06 | 0001628280-26-053817 | EDGAR | 2K words |
| 2026-03-11 | 0001628280-26-016805 | EDGAR | 2K words |
| 2026-02-23 | 0001628280-26-010377 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-009885 | EDGAR | 6K words |
| 2025-12-04 | 0001628280-25-055215 | EDGAR | 1K words |
| 2025-11-07 | 0001628280-25-050683 | EDGAR | 7K words |
| 2025-11-05 | 0001628280-25-049236 | EDGAR | 2K words |
| 2025-10-30 | 0001628280-25-047322 | EDGAR | 4K words |
| 2025-09-02 | 0001822462-25-000007 | EDGAR | 6K words |
127 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001822462 |
| Ticker | FHTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.foghorntx.com |
| Listed | 2020-10-23 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/FHTX (~200 tokens, structured JSON with cryptographic provenance)